Russia’s largest cloud service provider deploys ADVA FSP 3000 to answer fierce data growth
11.9.2019 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Inoventica has selected its FSP 3000 platform to meet soaring data demand from enterprise and carrier customers. Inoventica, one of Russia’s leading IT service providers and data center operators, will leverage the solution to boost the capacity of its backbone network to 100Gbit/s and beyond. The new fully redundant infrastructure leverages ADVA’s QuadFlex™ line card and OpenFabric™ cross-connect – two technologies optimized for efficiency and complete flexibility. ADVA’s Select partner, the IT solution specialist Zettaline is also playing a key role in facilitating the project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190911005024/en/
The FSP 3000 platform enables Inoventica to meet soaring data demand from enterprise and carrier customers (Photo: Business Wire)
“ADVA’s technology enables us to take the next step with our infrastructure while also leveraging maximum value from our existing network. With this deployment, we can flexibly respond to soaring data requirements and help our customers to unleash their full potential,” said Vitaly Slizen, CEO, Inoventica. “The ADVA FSP 3000 delivers several key efficiencies from low latency to optimized bandwidth utilization. And the FSP 3000 OpenFabric™ empowers us to cost-effectively provide the data rates our customers need by aggregating 1Gbit/s and 10Gbit/s services onto 100Gbit/s wavelengths. Furthermore, its openness means we can reap the benefits of unlimited innovation cycles in the future.”
Designed for scalability and bandwidth optimization, the ADVA FSP 3000 ensures that Inoventica’s new infrastructure offers superb efficiency. It enables significant energy savings and, with its 1RU footprint, occupies very little rack space. Using ADVA FSP 3000 QuadFlex™ technology, the solution will transport 100Gbit/s data loads over distances stretching to 2,000km across the Moscow metropolitan area. By enabling greater spectral efficiency, QuadFlex™ delivers extended reach without any need for signal regeneration. Also key is the ADVA FSP 3000 OpenFabric™, which creates a distributed architecture, enabling Inoventica to simply and efficiently aggregate lower-speed services.
“We’re proud that Russia’s largest cloud service provider has chosen to harness our technology and expertise. Together with our partner Zettaline, we’ve built a solution that efficiently expands Inoventica’s infrastructure and provides the tools it needs to address today’s key challenges,” commented Andreas Jelinek, senior director, sales, Eastern Europe, Russia and CIS, ADVA. “The new fully redundant solution is protected, flexible and extremely cost-efficient. It also meets all of Inoventica’s density, security and energy requirements. Furthermore, thanks to the modular, scalable design of our FSP 3000 platform and the ongoing support of our team, Inoventica is free to plan an exciting roadmap for further development in the future.”
“This deployment is going to bring substantial benefits to a great number of Russian enterprises and we’re proud to be playing such a big part in helping Inoventica take this leap forward. Working closely with our friends at ADVA, we’ve created a transport system that squeezes maximum value from Inoventica’s existing resources while enabling the flexibility and capacity necessary for the 5G and IoT era,” said Alexander Hochmuth, shareholder representative, Zettaline Ltd. “As a team, ADVA and Zettaline provide both global knowledge and local expertise. Together, we’ve designed an open, disaggregated and completely future-proof solution that meets all of Inoventica’s needs and ambitions.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com.
About Inoventica
INOVENTICA Group of Companies is the first Russian IT-operator that has been implementing projects based on innovative ICT Infrastructure of international scale based on cloud computing technologies since 1999. Partners and clients of the INOVENTICA Group of Companies are more than 5 thousand B2C subscribers, more than 1000 corporate clients (B2B), 48 national and international telecom operators. www.invs.ru
Published by:
ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190911005024/en/
Contact information
For ADVA press:
Gareth Spence
t +44 1904 699 358
public-relations@advaoptical.com
For ADVA investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@advaoptical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom